Oxaliplatin Injection, Solution
Product Images NDC 43066-014

This is a table showing the results of a clinical trial comparing two chemotherapy treatments (FOLFOX4 and LV5FU2) on disease-free survival (DFS) over a period of 6 years. The table shows the number of patients in each arm, the number of events (disease progression or death), and the percentage of patients experiencing events in each arm. The hazard ratio (HR) and its 95% confidence interval (CI) are also provided, along with the p-value from a stratified logrank test. The last row shows the number of patients at risk in each arm at different time points (in months) along the DFS curve.*

This is a graph that shows the probability of disease-free survival (DFS) over time (in months) for two treatment arms, FOLFOX4 and LV5FU2, in patients with Dukes C colon cancer. The hazard ratio for the two arms is 0.78 (95% CI: 0.65, 0.93), indicating a lower risk of disease progression or death with FOLFOX4. The logrank test was statistically significant (p=0.005). The graph shows that DFS probability is higher for FOLFOX4 during the entire follow-up period.*

This appears to be a graph that compares the median survival times and effectiveness of different chemotherapy treatments (Oxaliplatin + 5-FU/LV, Oxaliplatin + Irinotecan, and Irinotecan + 5-FU/LV) for an unknown medical condition. The graph also shows time in months and the results of a Log rank test, which indicates that the Oxaliplatin + 5-FU/LV treatment was significantly more effective than the Irinotecan + 5-FU/LV treatment.*

This appears to be a product label for a sterile aqueous solution medication, likely used for intravenous use. The medication contains oxaliplatin, a cytotoxic agent. The dosage is 50mg/10mL and it should be kept out of the reach of children and stored at room temperature. It is recommended not to mix or add with other solutions and should be used in a single-dose vial only. Further information can be found in the package insert.*

This text describes a pharmaceutical product for intravenous use only, called Oxaliplatin, which comes in a sterile aqueous solution. The solution contains 5 mg of oxaliplatin and water for injection per 1 mL of solution. The product is used as a cytotoxic agent and caution should be taken when handling or administering it. The solution is to be used with a single-dose vial only and shouldn't be mixed with or added to chloride-containing solutions. The solution shouldn't be frozen and should be protected from light. The text also specifies the storage conditions for this solution and mentions that unused portions should be discarded as instructed in the package insert. The product is manufactured by Baxter International Inc.*